Indaptus Therapeutics, Inc.

NASDAQ:INDP

Biotechnology

Healthcare
$3.32 -2.21%

-$0.03 today

Market cap
$375.96M
Beta
1.14
P/E (TTM)
-0.2
EPS (TTM)
-$8.70
52W Low $0.92High $8.69

Volume 0.28M

Average 0.97M

INDP EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Indaptus Therapeutics, Inc.NASDAQ: INDP

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$2.54M, compared with -$4.53M a year earlier. Trailing-twelve-month EBITDA was -$18.86M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -38.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.54M+68.7% QoQ
Last fiscal yearDec 2025
-$20.85M-38.8% YoY
LTMMar 2026
-$18.86M-19.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+43.9%+100.0%+56.1 pp
1 year-38.8%+100.0%+138.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(20.85M) USD
Year-over-year change
-38.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How INDP compares with its peers on the latest reported figures

  • INDP's LTM Mar 2026 EBITDA of -$18.86M is the lowest of the 2 companies compared; the peer median is -$5.1M.
  • Its year-over-year change of -19.7% is the lowest of 2, against a peer median of +42.6%.
INDP Competitors Peer median
EBITDA for INDP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AZTRAzitra, Inc.LTM Jun 2026-$5.1M +42.6%——
INDPIndaptus Therapeutics, Inc.LTM Mar 2026-$18.86M -19.7%——
Peer median (excluding INDP) -$5.1M+42.6%——

Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development2.52M6.32M7.62M7.25M9.34M
Selling, General & Admin5.21M8.59M8.76M8.11M10.49M
Operating Expenses7.73M14.91M16.38M15.37M19.83M
Depreciation & Amortization1.4K1.78K1.28K7350
EBITDA(7.71M)(14.32M)(15.42M)(15.02M)(20.85M)
EBITDA Margin—————
Operating Income(7.73M)(14.91M)(16.38M)(15.37M)(19.83M)
Operating Margin—————
Interest Income17.72K588.11K000
Interest Expense00000
Other Income / Expenses17.72K588.11K955K343.72K(1.02M)
Income Before Tax(7.71M)(14.32M)(15.42M)(15.02M)(20.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(7.71M)(14.32M)(15.42M)(15.02M)(20.85M)
Net Margin—————
EPS (Basic)(1.89)(1.73)(1.84)(1.61)(21.58)
EPS (Diluted)(1.89)(1.73)(1.84)(1.61)(21.58)
Weighted Avg Shares4.09M8.26M8.4M9.36M966.12K
Weighted Avg Shares (Diluted)4.09M8.26M8.4M9.36M966.12K

Indaptus Therapeutics, Inc.

NASDAQ:INDP

Intrinsic Alpha fair value

Locked

Current Price

$3.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.